nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—SLCO1B1—Methotrexate—muscle cancer	0.369	1	CbGbCtD
Penicillamine—Leukaemia—Vincristine—muscle cancer	0.0254	0.0402	CcSEcCtD
Penicillamine—Guillain-Barre syndrome—Methotrexate—muscle cancer	0.0229	0.0362	CcSEcCtD
Penicillamine—Alveolitis allergic—Methotrexate—muscle cancer	0.0127	0.0201	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Etoposide—muscle cancer	0.0126	0.02	CcSEcCtD
Penicillamine—Eruption—Dactinomycin—muscle cancer	0.0124	0.0197	CcSEcCtD
Penicillamine—Leukaemia—Methotrexate—muscle cancer	0.0123	0.0195	CcSEcCtD
Penicillamine—Interstitial pneumonia—Etoposide—muscle cancer	0.0115	0.0182	CcSEcCtD
Penicillamine—Leukaemia—Doxorubicin—muscle cancer	0.0107	0.0169	CcSEcCtD
Penicillamine—Bone marrow depression—Vincristine—muscle cancer	0.0101	0.0161	CcSEcCtD
Penicillamine—Coagulopathy—Dactinomycin—muscle cancer	0.00983	0.0156	CcSEcCtD
Penicillamine—Optic neuritis—Etoposide—muscle cancer	0.009	0.0143	CcSEcCtD
Penicillamine—Extravasation—Dactinomycin—muscle cancer	0.00877	0.0139	CcSEcCtD
Penicillamine—Extravasation—Vincristine—muscle cancer	0.00784	0.0124	CcSEcCtD
Penicillamine—Interstitial lung disease—Etoposide—muscle cancer	0.00782	0.0124	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Methotrexate—muscle cancer	0.00754	0.012	CcSEcCtD
Penicillamine—Aplastic anaemia—Dactinomycin—muscle cancer	0.00718	0.0114	CcSEcCtD
Penicillamine—Mouth ulceration—Dactinomycin—muscle cancer	0.00692	0.011	CcSEcCtD
Penicillamine—Interstitial pneumonia—Methotrexate—muscle cancer	0.00686	0.0109	CcSEcCtD
Penicillamine—Appetite absent—Methotrexate—muscle cancer	0.00667	0.0106	CcSEcCtD
Penicillamine—Neuropathy—Vincristine—muscle cancer	0.00642	0.0102	CcSEcCtD
Penicillamine—Extravasation—Etoposide—muscle cancer	0.00635	0.0101	CcSEcCtD
Penicillamine—Mouth ulceration—Vincristine—muscle cancer	0.00618	0.0098	CcSEcCtD
Penicillamine—Hepatic failure—Dactinomycin—muscle cancer	0.00618	0.0098	CcSEcCtD
Penicillamine—Hepatic failure—Vincristine—muscle cancer	0.00552	0.00875	CcSEcCtD
Penicillamine—Eruption—Methotrexate—muscle cancer	0.00539	0.00855	CcSEcCtD
Penicillamine—Neuropathy—Etoposide—muscle cancer	0.0052	0.00824	CcSEcCtD
Penicillamine—Mouth ulceration—Etoposide—muscle cancer	0.00501	0.00794	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.005	0.00793	CcSEcCtD
Penicillamine—Bone marrow depression—Methotrexate—muscle cancer	0.00491	0.00779	CcSEcCtD
Penicillamine—Interstitial lung disease—Methotrexate—muscle cancer	0.00469	0.00743	CcSEcCtD
Penicillamine—Eruption—Doxorubicin—muscle cancer	0.00467	0.0074	CcSEcCtD
Penicillamine—Optic neuritis—Doxorubicin—muscle cancer	0.00467	0.0074	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00462	0.00732	CcSEcCtD
Penicillamine—Thrombocytosis—Doxorubicin—muscle cancer	0.00462	0.00732	CcSEcCtD
Penicillamine—Pancytopenia—Dactinomycin—muscle cancer	0.00456	0.00723	CcSEcCtD
Penicillamine—Muscular weakness—Vincristine—muscle cancer	0.00438	0.00694	CcSEcCtD
Penicillamine—Bone marrow depression—Doxorubicin—muscle cancer	0.00425	0.00674	CcSEcCtD
Penicillamine—Stomatitis—Dactinomycin—muscle cancer	0.00417	0.00661	CcSEcCtD
Penicillamine—Pancytopenia—Vincristine—muscle cancer	0.00407	0.00646	CcSEcCtD
Penicillamine—Agranulocytosis—Dactinomycin—muscle cancer	0.00399	0.00633	CcSEcCtD
Penicillamine—Extravasation—Methotrexate—muscle cancer	0.0038	0.00603	CcSEcCtD
Penicillamine—Proteinuria—Methotrexate—muscle cancer	0.00378	0.00598	CcSEcCtD
Penicillamine—Rash erythematous—Doxorubicin—muscle cancer	0.00375	0.00594	CcSEcCtD
Penicillamine—Neuropathy peripheral—Vincristine—muscle cancer	0.00375	0.00594	CcSEcCtD
Penicillamine—Stomatitis—Vincristine—muscle cancer	0.00373	0.00591	CcSEcCtD
Penicillamine—Protein urine present—Methotrexate—muscle cancer	0.00372	0.0059	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00362	0.00574	CcSEcCtD
Penicillamine—Glossitis—Methotrexate—muscle cancer	0.0036	0.0057	CcSEcCtD
Penicillamine—Ageusia—Doxorubicin—muscle cancer	0.00355	0.00562	CcSEcCtD
Penicillamine—Vasculitis—Methotrexate—muscle cancer	0.0034	0.00539	CcSEcCtD
Penicillamine—Alopecia—Dactinomycin—muscle cancer	0.0034	0.00538	CcSEcCtD
Penicillamine—Urinary tract disorder—Vincristine—muscle cancer	0.00339	0.00537	CcSEcCtD
Penicillamine—Urethral disorder—Vincristine—muscle cancer	0.00337	0.00533	CcSEcCtD
Penicillamine—Pancytopenia—Etoposide—muscle cancer	0.0033	0.00523	CcSEcCtD
Penicillamine—Extravasation—Doxorubicin—muscle cancer	0.00329	0.00522	CcSEcCtD
Penicillamine—Glossitis—Doxorubicin—muscle cancer	0.00312	0.00494	CcSEcCtD
Penicillamine—Angiopathy—Vincristine—muscle cancer	0.00311	0.00494	CcSEcCtD
Penicillamine—Aplastic anaemia—Methotrexate—muscle cancer	0.00311	0.00494	CcSEcCtD
Penicillamine—Anaemia—Dactinomycin—muscle cancer	0.00309	0.0049	CcSEcCtD
Penicillamine—Renal failure—Etoposide—muscle cancer	0.00305	0.00483	CcSEcCtD
Penicillamine—Neuropathy peripheral—Etoposide—muscle cancer	0.00304	0.00481	CcSEcCtD
Penicillamine—Alopecia—Vincristine—muscle cancer	0.00303	0.00481	CcSEcCtD
Penicillamine—Stomatitis—Etoposide—muscle cancer	0.00302	0.00479	CcSEcCtD
Penicillamine—Mental disorder—Vincristine—muscle cancer	0.00301	0.00477	CcSEcCtD
Penicillamine—Mouth ulceration—Methotrexate—muscle cancer	0.003	0.00475	CcSEcCtD
Penicillamine—Leukopenia—Dactinomycin—muscle cancer	0.00299	0.00475	CcSEcCtD
Penicillamine—Hepatobiliary disease—Etoposide—muscle cancer	0.00293	0.00464	CcSEcCtD
Penicillamine—Agranulocytosis—Etoposide—muscle cancer	0.00289	0.00458	CcSEcCtD
Penicillamine—Lymphadenopathy—Methotrexate—muscle cancer	0.00282	0.00447	CcSEcCtD
Penicillamine—Thrombophlebitis—Methotrexate—muscle cancer	0.00278	0.00441	CcSEcCtD
Penicillamine—Anaemia—Vincristine—muscle cancer	0.00276	0.00438	CcSEcCtD
Penicillamine—Urinary tract disorder—Etoposide—muscle cancer	0.00275	0.00435	CcSEcCtD
Penicillamine—Agitation—Vincristine—muscle cancer	0.00275	0.00435	CcSEcCtD
Penicillamine—Urethral disorder—Etoposide—muscle cancer	0.00273	0.00432	CcSEcCtD
Penicillamine—Aplastic anaemia—Doxorubicin—muscle cancer	0.0027	0.00427	CcSEcCtD
Penicillamine—Neuropathy—Doxorubicin—muscle cancer	0.0027	0.00427	CcSEcCtD
Penicillamine—Hepatic failure—Methotrexate—muscle cancer	0.00268	0.00425	CcSEcCtD
Penicillamine—Leukopenia—Vincristine—muscle cancer	0.00268	0.00424	CcSEcCtD
Penicillamine—Thrombocytopenia—Dactinomycin—muscle cancer	0.00267	0.00424	CcSEcCtD
Penicillamine—Anorexia—Dactinomycin—muscle cancer	0.0026	0.00412	CcSEcCtD
Penicillamine—Mouth ulceration—Doxorubicin—muscle cancer	0.0026	0.00412	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Methotrexate—muscle cancer	0.00255	0.00404	CcSEcCtD
Penicillamine—Angiopathy—Etoposide—muscle cancer	0.00252	0.004	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00249	0.00394	CcSEcCtD
Penicillamine—Alopecia—Etoposide—muscle cancer	0.00246	0.00389	CcSEcCtD
Penicillamine—Lymphadenopathy—Doxorubicin—muscle cancer	0.00244	0.00387	CcSEcCtD
Penicillamine—Thrombophlebitis—Doxorubicin—muscle cancer	0.00241	0.00382	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.0024	0.0038	CcSEcCtD
Penicillamine—Thrombocytopenia—Vincristine—muscle cancer	0.00239	0.00378	CcSEcCtD
Penicillamine—Hepatic function abnormal—Doxorubicin—muscle cancer	0.00239	0.00378	CcSEcCtD
Penicillamine—Decreased appetite—Dactinomycin—muscle cancer	0.00237	0.00376	CcSEcCtD
Penicillamine—Dysgeusia—Etoposide—muscle cancer	0.00237	0.00376	CcSEcCtD
Penicillamine—Anorexia—Vincristine—muscle cancer	0.00232	0.00368	CcSEcCtD
Penicillamine—Hepatic failure—Doxorubicin—muscle cancer	0.00232	0.00368	CcSEcCtD
Penicillamine—Anaemia—Etoposide—muscle cancer	0.00224	0.00355	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00222	0.00352	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.00221	0.0035	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00217	0.00344	CcSEcCtD
Penicillamine—Leukopenia—Etoposide—muscle cancer	0.00217	0.00343	CcSEcCtD
Penicillamine—Body temperature increased—Dactinomycin—muscle cancer	0.00216	0.00342	CcSEcCtD
Penicillamine—Hypoglycaemia—Doxorubicin—muscle cancer	0.00214	0.00339	CcSEcCtD
Penicillamine—Decreased appetite—Vincristine—muscle cancer	0.00212	0.00336	CcSEcCtD
Penicillamine—Asthma—Methotrexate—muscle cancer	0.00208	0.0033	CcSEcCtD
Penicillamine—Eosinophilia—Methotrexate—muscle cancer	0.00206	0.00327	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00205	0.00324	CcSEcCtD
Penicillamine—Pancreatitis—Methotrexate—muscle cancer	0.00204	0.00323	CcSEcCtD
Penicillamine—Hypersensitivity—Dactinomycin—muscle cancer	0.00201	0.00319	CcSEcCtD
Penicillamine—Pancytopenia—Methotrexate—muscle cancer	0.00198	0.00313	CcSEcCtD
Penicillamine—Thrombocytopenia—Etoposide—muscle cancer	0.00193	0.00307	CcSEcCtD
Penicillamine—Body temperature increased—Vincristine—muscle cancer	0.00193	0.00306	CcSEcCtD
Penicillamine—Skin disorder—Etoposide—muscle cancer	0.00192	0.00304	CcSEcCtD
Penicillamine—Abdominal pain upper—Doxorubicin—muscle cancer	0.0019	0.00302	CcSEcCtD
Penicillamine—Anorexia—Etoposide—muscle cancer	0.00188	0.00298	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00188	0.00298	CcSEcCtD
Penicillamine—Diarrhoea—Dactinomycin—muscle cancer	0.00187	0.00296	CcSEcCtD
Penicillamine—Muscular weakness—Doxorubicin—muscle cancer	0.00184	0.00291	CcSEcCtD
Penicillamine—Renal failure—Methotrexate—muscle cancer	0.00182	0.00289	CcSEcCtD
Penicillamine—Stomatitis—Methotrexate—muscle cancer	0.00181	0.00287	CcSEcCtD
Penicillamine—Asthma—Doxorubicin—muscle cancer	0.0018	0.00286	CcSEcCtD
Penicillamine—Hypersensitivity—Vincristine—muscle cancer	0.0018	0.00285	CcSEcCtD
Penicillamine—Eosinophilia—Doxorubicin—muscle cancer	0.00178	0.00283	CcSEcCtD
Penicillamine—Haematuria—Methotrexate—muscle cancer	0.00177	0.0028	CcSEcCtD
Penicillamine—Pancreatitis—Doxorubicin—muscle cancer	0.00177	0.0028	CcSEcCtD
Penicillamine—Hepatobiliary disease—Methotrexate—muscle cancer	0.00175	0.00278	CcSEcCtD
Penicillamine—Vomiting—Dactinomycin—muscle cancer	0.00174	0.00275	CcSEcCtD
Penicillamine—Agranulocytosis—Methotrexate—muscle cancer	0.00173	0.00274	CcSEcCtD
Penicillamine—Rash—Dactinomycin—muscle cancer	0.00172	0.00273	CcSEcCtD
Penicillamine—Decreased appetite—Etoposide—muscle cancer	0.00172	0.00272	CcSEcCtD
Penicillamine—Pancytopenia—Doxorubicin—muscle cancer	0.00171	0.00271	CcSEcCtD
Penicillamine—Haemoglobin—Methotrexate—muscle cancer	0.00167	0.00265	CcSEcCtD
Penicillamine—Diarrhoea—Vincristine—muscle cancer	0.00167	0.00264	CcSEcCtD
Penicillamine—Haemorrhage—Methotrexate—muscle cancer	0.00167	0.00264	CcSEcCtD
Penicillamine—Urinary tract disorder—Methotrexate—muscle cancer	0.00165	0.00261	CcSEcCtD
Penicillamine—Urethral disorder—Methotrexate—muscle cancer	0.00163	0.00259	CcSEcCtD
Penicillamine—Nausea—Dactinomycin—muscle cancer	0.00162	0.00257	CcSEcCtD
Penicillamine—Renal failure—Doxorubicin—muscle cancer	0.00158	0.0025	CcSEcCtD
Penicillamine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00157	0.0025	CcSEcCtD
Penicillamine—Urticaria—Etoposide—muscle cancer	0.00157	0.00249	CcSEcCtD
Penicillamine—Stomatitis—Doxorubicin—muscle cancer	0.00157	0.00248	CcSEcCtD
Penicillamine—Body temperature increased—Etoposide—muscle cancer	0.00156	0.00248	CcSEcCtD
Penicillamine—Tinnitus—Methotrexate—muscle cancer	0.00155	0.00246	CcSEcCtD
Penicillamine—Vomiting—Vincristine—muscle cancer	0.00155	0.00246	CcSEcCtD
Penicillamine—Rash—Vincristine—muscle cancer	0.00154	0.00244	CcSEcCtD
Penicillamine—Dermatitis—Vincristine—muscle cancer	0.00154	0.00244	CcSEcCtD
Penicillamine—Haematuria—Doxorubicin—muscle cancer	0.00153	0.00243	CcSEcCtD
Penicillamine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00152	0.00241	CcSEcCtD
Penicillamine—Angiopathy—Methotrexate—muscle cancer	0.00151	0.0024	CcSEcCtD
Penicillamine—Agranulocytosis—Doxorubicin—muscle cancer	0.0015	0.00238	CcSEcCtD
Penicillamine—Alopecia—Methotrexate—muscle cancer	0.00147	0.00233	CcSEcCtD
Penicillamine—Mental disorder—Methotrexate—muscle cancer	0.00146	0.00231	CcSEcCtD
Penicillamine—Hypersensitivity—Etoposide—muscle cancer	0.00146	0.00231	CcSEcCtD
Penicillamine—Haemoglobin—Doxorubicin—muscle cancer	0.00145	0.0023	CcSEcCtD
Penicillamine—Nausea—Vincristine—muscle cancer	0.00145	0.0023	CcSEcCtD
Penicillamine—Haemorrhage—Doxorubicin—muscle cancer	0.00144	0.00229	CcSEcCtD
Penicillamine—Urinary tract disorder—Doxorubicin—muscle cancer	0.00142	0.00226	CcSEcCtD
Penicillamine—Dysgeusia—Methotrexate—muscle cancer	0.00142	0.00225	CcSEcCtD
Penicillamine—Urethral disorder—Doxorubicin—muscle cancer	0.00141	0.00224	CcSEcCtD
Penicillamine—Diarrhoea—Etoposide—muscle cancer	0.00135	0.00214	CcSEcCtD
Penicillamine—Tinnitus—Doxorubicin—muscle cancer	0.00134	0.00213	CcSEcCtD
Penicillamine—Anaemia—Methotrexate—muscle cancer	0.00134	0.00212	CcSEcCtD
Penicillamine—Angiopathy—Doxorubicin—muscle cancer	0.00131	0.00207	CcSEcCtD
Penicillamine—Leukopenia—Methotrexate—muscle cancer	0.0013	0.00206	CcSEcCtD
Penicillamine—Alopecia—Doxorubicin—muscle cancer	0.00127	0.00202	CcSEcCtD
Penicillamine—Mental disorder—Doxorubicin—muscle cancer	0.00126	0.002	CcSEcCtD
Penicillamine—Vomiting—Etoposide—muscle cancer	0.00126	0.00199	CcSEcCtD
Penicillamine—Rash—Etoposide—muscle cancer	0.00125	0.00197	CcSEcCtD
Penicillamine—Dermatitis—Etoposide—muscle cancer	0.00124	0.00197	CcSEcCtD
Penicillamine—Arthralgia—Methotrexate—muscle cancer	0.00123	0.00196	CcSEcCtD
Penicillamine—Dysgeusia—Doxorubicin—muscle cancer	0.00123	0.00195	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00123	0.00194	CcSEcCtD
Penicillamine—Nausea—Etoposide—muscle cancer	0.00117	0.00186	CcSEcCtD
Penicillamine—Anaemia—Doxorubicin—muscle cancer	0.00116	0.00184	CcSEcCtD
Penicillamine—Thrombocytopenia—Methotrexate—muscle cancer	0.00116	0.00184	CcSEcCtD
Penicillamine—Agitation—Doxorubicin—muscle cancer	0.00115	0.00183	CcSEcCtD
Penicillamine—Skin disorder—Methotrexate—muscle cancer	0.00115	0.00182	CcSEcCtD
Penicillamine—Anorexia—Methotrexate—muscle cancer	0.00113	0.00179	CcSEcCtD
Penicillamine—Leukopenia—Doxorubicin—muscle cancer	0.00112	0.00178	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00108	0.00171	CcSEcCtD
Penicillamine—Arthralgia—Doxorubicin—muscle cancer	0.00107	0.00169	CcSEcCtD
Penicillamine—Anxiety—Doxorubicin—muscle cancer	0.00107	0.00169	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00106	0.00168	CcSEcCtD
Penicillamine—Decreased appetite—Methotrexate—muscle cancer	0.00103	0.00163	CcSEcCtD
Penicillamine—Thrombocytopenia—Doxorubicin—muscle cancer	0.001	0.00159	CcSEcCtD
Penicillamine—Skin disorder—Doxorubicin—muscle cancer	0.000995	0.00158	CcSEcCtD
Penicillamine—Anorexia—Doxorubicin—muscle cancer	0.000977	0.00155	CcSEcCtD
Penicillamine—Urticaria—Methotrexate—muscle cancer	0.00094	0.00149	CcSEcCtD
Penicillamine—Body temperature increased—Methotrexate—muscle cancer	0.000936	0.00148	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000934	0.00148	CcSEcCtD
Penicillamine—Decreased appetite—Doxorubicin—muscle cancer	0.000891	0.00141	CcSEcCtD
Penicillamine—Hypersensitivity—Methotrexate—muscle cancer	0.000872	0.00138	CcSEcCtD
Penicillamine—Urticaria—Doxorubicin—muscle cancer	0.000814	0.00129	CcSEcCtD
Penicillamine—Body temperature increased—Doxorubicin—muscle cancer	0.00081	0.00128	CcSEcCtD
Penicillamine—Diarrhoea—Methotrexate—muscle cancer	0.00081	0.00128	CcSEcCtD
Penicillamine—Hypersensitivity—Doxorubicin—muscle cancer	0.000755	0.0012	CcSEcCtD
Penicillamine—Vomiting—Methotrexate—muscle cancer	0.000752	0.00119	CcSEcCtD
Penicillamine—Rash—Methotrexate—muscle cancer	0.000746	0.00118	CcSEcCtD
Penicillamine—Dermatitis—Methotrexate—muscle cancer	0.000745	0.00118	CcSEcCtD
Penicillamine—Nausea—Methotrexate—muscle cancer	0.000703	0.00111	CcSEcCtD
Penicillamine—Diarrhoea—Doxorubicin—muscle cancer	0.000701	0.00111	CcSEcCtD
Penicillamine—Vomiting—Doxorubicin—muscle cancer	0.000652	0.00103	CcSEcCtD
Penicillamine—Rash—Doxorubicin—muscle cancer	0.000646	0.00102	CcSEcCtD
Penicillamine—Dermatitis—Doxorubicin—muscle cancer	0.000646	0.00102	CcSEcCtD
Penicillamine—Nausea—Doxorubicin—muscle cancer	0.000609	0.000965	CcSEcCtD
